MC

706.3

+2.36%↑

ALV

329.6

+2.11%↑

SAF

246

-0.16%↓

BNP

70.19

-1.06%↓

MUV2

529.8

+0.49%↑

MC

706.3

+2.36%↑

ALV

329.6

+2.11%↑

SAF

246

-0.16%↓

BNP

70.19

-1.06%↓

MUV2

529.8

+0.49%↑

MC

706.3

+2.36%↑

ALV

329.6

+2.11%↑

SAF

246

-0.16%↓

BNP

70.19

-1.06%↓

MUV2

529.8

+0.49%↑

MC

706.3

+2.36%↑

ALV

329.6

+2.11%↑

SAF

246

-0.16%↓

BNP

70.19

-1.06%↓

MUV2

529.8

+0.49%↑

MC

706.3

+2.36%↑

ALV

329.6

+2.11%↑

SAF

246

-0.16%↓

BNP

70.19

-1.06%↓

MUV2

529.8

+0.49%↑

Search

Bayer AG

Abierto

Sector Finanzas

21.365 1.18

Resumen

Variación precio

24h

Actual

Mínimo

20.715

Máximo

21.485

Métricas clave

By Trading Economics

Ingresos

-4.1B

-4.2B

Ventas

-1.2B

10B

P/B

Media del Sector

30.9

28.396

BPA

0.24

Rentabilidad por dividendo

0.363

Margen de beneficio

-41.956

EBITDA

3.3B

5B

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+23.44 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.36%

3.54%

Próximas Ganancias

5 mar 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

21B

Apertura anterior

20.18

Cierre anterior

21.365

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

161 / 545 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Bayer AG Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

12 nov 2024, 09:32 UTC

Ganancias

Bayer Cuts Earnings Target, Warns on Weak Agriculture Market -- Update

12 nov 2024, 07:21 UTC

Ganancias

Bayer Cuts Earnings Target, Posts Net Loss on Agriculture Weakness

13 ene 2025, 21:05 UTC

Principales Noticias

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

9 ene 2025, 15:06 UTC

Adquisiciones, fusiones, absorciones

Bayer Didn't Disclose Financial Details

9 ene 2025, 15:05 UTC

Adquisiciones, fusiones, absorciones

Bayer: Goal Is to Help Decarbonize Transportation Sector With Advancing Innovative Crops

9 ene 2025, 15:05 UTC

Adquisiciones, fusiones, absorciones

Bayer: Camelina Is Novel Intermediate Oilseed Crop

9 ene 2025, 15:04 UTC

Adquisiciones, fusiones, absorciones

Bayer: Smart Earth Camelina Is Headquartered in Saskatoon, Saskatchewan, Canada

9 ene 2025, 15:03 UTC

Adquisiciones, fusiones, absorciones

Bayer: Deal Expands Position in Biomass-Based Feedstock Markets

9 ene 2025, 15:02 UTC

Adquisiciones, fusiones, absorciones

Bayer Acquires Camelina Germplasm, Intellectual Property Assets

9 ene 2025, 15:02 UTC

Adquisiciones, fusiones, absorciones

Bayer, Smart Earth Camelina Corp Have Closed Deal

9 ene 2025, 15:01 UTC

Adquisiciones, fusiones, absorciones

Bayer Acquires Camelina Assets From Smart Earth Camelina Corp

8 ene 2025, 13:07 UTC

Adquisiciones, fusiones, absorciones

Bayer Doesn't Disclose Financial Details

8 ene 2025, 13:06 UTC

Adquisiciones, fusiones, absorciones

Bayer: Vividion and Tavros Have Been Working Together for the Past Two Years

8 ene 2025, 13:05 UTC

Adquisiciones, fusiones, absorciones

Bayer: Acquisition Will Expand Functional Genomics Capabilities, Boost Drug Discovery Platform

8 ene 2025, 13:05 UTC

Adquisiciones, fusiones, absorciones

Bayer: Tavros Therapeutics Is a Precision Oncology Platform Company

8 ene 2025, 13:04 UTC

Adquisiciones, fusiones, absorciones

Bayer: Acquisition Builds on Successful Collaboration Focused on Promising Drug Targets in Oncology

8 ene 2025, 13:03 UTC

Adquisiciones, fusiones, absorciones

Bayer: Vividion Therapeutics Is a Wholly Owned and Independently Operating Subsidiary of Bayer

8 ene 2025, 13:02 UTC

Adquisiciones, fusiones, absorciones

Bayer: Vividion Therapeutics to Acquire Tavros Therapeutics

12 nov 2024, 16:39 UTC

Charlas de Mercado

Despite Rhetoric, Bayer CEO Says Pesticides Needed -- Market Talk

12 nov 2024, 10:16 UTC

Charlas de Mercado
Ganancias

Bayer's Pharmaceutical Sales Beat Market Expectations -- Market Talk

12 nov 2024, 09:53 UTC

Ganancias
Acciones populares

Stocks to Watch Tuesday: Tesla, SoftBank, Spirit Airlines, Home Depot -- WSJ

12 nov 2024, 09:43 UTC

Charlas de Mercado
Ganancias

Bayer's Earnings Came in Below Market Expectations -- Market Talk

12 nov 2024, 07:53 UTC

Principales Noticias
Ganancias

Correct: Analysts Had Forecast Bayer 3Q Net Loss of EUR579M

12 nov 2024, 07:02 UTC

Ganancias

AstraZeneca Had Seen 2024 Core EPS Growth by Mid Teens Percentage Range

12 nov 2024, 07:02 UTC

Ganancias

AstraZeneca Sees 2024 Core EPS Growth In High Teens Percentage Range

12 nov 2024, 07:02 UTC

Ganancias

AstraZeneca Had Seen 2024 Total Revenue Growth In Mid Teens Percentage Range

12 nov 2024, 07:02 UTC

Ganancias

AstraZeneca Sees 2024 Total Revenue Growth In High Teens Percentage Range

12 nov 2024, 07:02 UTC

Ganancias

AstraZeneca Raises 2024 View

12 nov 2024, 07:01 UTC

Ganancias

Analysts Saw AstraZeneca 3Q Sales at $13.1B

12 nov 2024, 07:01 UTC

Ganancias

Analysts Saw AstraZeneca 3Q Core EPS at $2.04

Comparación entre iguales

Cambio de precio

Bayer AG Esperado

Precio Objetivo

By TipRanks

23.44% repunte

Estimación a 12 meses

Media 25.59 EUR  23.44%

Máximo 33 EUR

Mínimo 22 EUR

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bayer AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

13 ratings

1

Comprar

12

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 21.235Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

161 / 545 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.